Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein of interest (POI) degradation refers to the targeted removal of specific proteins within a cell, typically through engineered or natural cellular pathways. This process is essential for maintaining protein homeostasis and regulating various cellular functions. Targeted protein degradation, often achieved through technologies like PROTACs and molecular glues, has emerged as a powerful strategy in drug discovery and research for eliminating disease-associated proteins that are otherwise difficult to inhibit with traditional small molecules. This approach involves recruiting E3 ubiquitin ligases to tag target proteins for degradation by the proteasome or lysosome, offering a catalytic mechanism and the potential to address resistance arising from mutations in the target.
Recruitment of E3 ubiquitin ligase to target protein leading to ubiquitination and subsequent degradation via the proteasome or lysosome.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein of Interest Degradation (POI Degradation).